Signaling pathway revealed through which a promising anti-leukemia drug kills cancer cells

14 mayo 2015

Due to overwhelming evidence of their effectiveness in mice, inhibitors of the leukemia protein BRD4, including the drug JQ1, moved into clinical trials starting in 2013. There are 12 trials targeting BRD4 in progress. Last year, clinical trial findings indicated that an oral inhibitor of BRD4 similar to JQ1 had led to complete remission in some patients. Now a team of researchers has determined the pathway through which JQ1 acts.